Our offices in The Villages and Orlando will be closed on Wed. & Thurs., Oct. 9–10. Also, our community events are cancelled Wed. & Thurs. We plan to reopen our offices and hold community events on Friday, Oct. 11. Check back here for updates.
We’re thrilled that you want to participate in researching healthier futures. Please select one of the ways to get involved below.
Refer a friend or family member to join research study today and you will receive a $55 Visa gift card when they enroll.
Pick a friend or a family member who is new to Charter Research.
Fill out the form below.
Early Alzheimer’s Combination Therapy Study
Lecanemab Paired With a New Anti-Tau Medication
This study looks at whether anti-amyloid and anti-tau medications used together could slow the progression of Alzheimer's disease.
You may have heard about lecanemab (Leqembi) in the news over the past year, that it is one of the latest FDA-approved drugs to help in the fight against Alzheimer’s. Did you know that even though drugs like this are approved for the public, pharmaceutical companies continue to research their benefits? This study looks at the benefits of lecanemab when it’s paired with a new anti-tau investigational drug.
This study is located at our research center in The Villages.
| READ MORE ABOUT THIS STUDY |
You may qualify for this study if:
Schedule Your Assessment
Sign up for an initial assessment (called a “prescreen”), and we'll give you a call. One of our professional medical staff will answer your questions and give you more information about Charter Research prior to an in-office visit.
